New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07421856
Summary
This early-stage trial is testing a new personalized cell therapy called S103 for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them to target the cancer, and infuse them back. The main goals are to find a safe dose and see if this one-time treatment can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.